Previous 10 | Next 10 |
Summary Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology. The key pipeline programs could have a peak reve...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood is continuing her streak of betting on beaten-down stocks. The founder of Ark Investment Management recently purchased 132,213 shares of Tesla (NASDAQ: TSLA ). In perfect Wood fashion, this comes after a...
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following u...
Verve Therapeutics ( NASDAQ: VERV ) said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) clearance its application to start a trial of its gene editing medicine VERVE-101 to treat patients with heterozygous familial hyperchol...
CAMBRIDGE, Mass., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the clearance of its Clinical Trial Authorisa...
Summary ARKG component added to flagship fund. Meaningful position would top 7% of outstanding shares. Company fits usual pattern with large losses and cash burn. For further details see: Verve Therapeutics: Cathie Wood Adds To ARKK
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a difficult year for Cathie Wood stocks and exchange-traded funds, as the ARK Innovation ETF (NYSEARCA: ARKK ) has lost over 50% of its market capitalization. The losses have been driven by suppl...
Summary Today, we put mid-cap biotech concern Beam Therapeutics Inc. in the spotlight for the first time. Beam Therapeutics is advancing its pipeline on a wide front and the stock has had a nice ride over the past few months. However, most of Beam's candidates are very early s...
Verve Therapeutics (NASDAQ: VERV) , a clinical-stage gene-editing company focusing on cardiovascular disease, saw its shares race higher this week by a healthy 17.1%, according to data from S&P Global Intelligence . The biotech's stock jumped this week for three key reasons:...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...